Pfizer completes acquisition of Ferrosan Consumer Health’s Business
Publication date: 1 December 2011
Author: Pfizer
Tagged with: Ferrosan Consumer Health, Paul Sturman, Pfizer
Pfizer Inc. (NYSE:PFE) today announced that it has completed its previously announced acquisition of Ferrosan Consumer Health’s business, which includes dietary supplements and lifestyle products, from Altor 2003 Fund GP Limited.
“Ferrosan Consumer Health’s innovative products and geographic footprint are a strong fit for our business,” said Paul Sturman, President, Pfizer Consumer Healthcare. “Today, we have taken an important step by adding leading brands to our existing portfolio as well as enhancing our presence in established and emerging markets such as the Nordic countries, Russia and Ukraine. Through this acquisition, we’ll have the opportunity to provide a broader portfolio of highly trusted and differentiated products to consumers.”
Advertisement:
Email newsletter
If you enjoyed this article sign-up to receive our bi-weekly email newsletter:
Latest news
- Novartis NVA237 Phase III data showed rapid, sustained improvement in lung function and symptom relief over one year in COPD patients (17 May 2012)
- Amgen’s BiTE® Antibody Blinatumomab achieved high rate of complete response in adult patients with relapsed or refractory acute lymphoblastic leukemia (16 May 2012)
- GlaxoSmithKline completes transaction to increase its ownership in Theravance (16 May 2012)
- Catalent announces winners of Global Academic Competition for Life Science Leaders of Tomorrow (16 May 2012)
- Roche will report new data on important progress for people with advanced cancers at ASCO 2012 (16 May 2012)
In-depth focus:
Mass Spectrometry
This free to view Mass Spectrometry in-depth focus is sponsored by Waters, Bruker, Protea and Dr. Hochmuth and contains the following articles:
- Mass spectrometry in drug discovery - Proteomics, small molecules and metablomics
- Quantification of membrane drug transporters and application in drug discovery and development
- Anthony Bristow, AstraZeneca, poses the questions for our Mass Spectrometry Leaders Roundtable
Company directory
ABB Analytical Measurements | Almac | B&W Tek, Inc. | BASF | BD Diagnostics | Bio-Optronics, Inc. | bioMérieux | BioTek Instruments, Inc. | Bruker Optics | CAMO Software AS | Catalent Pharma Solutions | Chemspec Europe Ltd | CI Precision | Cisbio Bioassays | EMD Millipore | GE Analytical Instruments | Gerresheimer Group | HACH LANGE GMBH | HORIBA Scientific | I Holland Limited | Lonza | Merck Millipore | Pall Life Sciences | Patheon Inc | Phenomenex | Porvair Sciences Ltd | Randox Pharma Services | Rapid Micro Biosystems | Realia | Roche | rommelag® | Umetrics |
Login to access exclusive content